Catalog No.
DHD80823
Expression system
Mammalian cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa-IgG1-Fab (Trispecific Antibody)
Target
Cyclic ADP-ribose hydrolase 1, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase, T10, 2'-phospho-cyclic-ADP-ribose transferase, CD38, ADPRC 1, ADP-ribosyl cyclase 1, 2'-phospho-ADP-ribosyl cyclase, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain, Tumor necrosis factor receptor superfamily member 17, TNFRSF17, CD269, B-cell maturation protein, BCMA, BCM
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P28907 & Q02223 & P07766
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies., PMID:39941892
Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab., PMID:39865264
Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives., PMID:39676006
A Phase 1/2 study of teclistamab, a humanized BCMA × CD3 bispecific Ab in Japanese patients with relapsed/refractory MM., PMID:39607603
Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US20240132615., PMID:39460602
A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies., PMID:39308023
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study., PMID:38657201
Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023-A Podcast., PMID:38642197
Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies., PMID:38421887
Elranatamab: First Approval., PMID:37924427
Teclistamab-cqyv in multiple myeloma., PMID:37848191
Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting., PMID:37509726
Antibodies and bispecifics for multiple myeloma: effective effector therapy., PMID:36485135
Teclistamab: First Approval., PMID:36352205
Teclistamab in Relapsed or Refractory Multiple Myeloma., PMID:35661166
[Bispecific antibodies in multiple myeloma]., PMID:34920804
Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma., PMID:34640611
Bispecifics, trispecifics, and other novel immune treatments in myeloma., PMID:33275733
Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: Advancing Antibody-Based Cancer Therapies to the Clinic., PMID:31844838
For research use only. Not for human or drug use.
